anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Research on Long COVID risk factors is ongoing. High body mass index (BMI) may increase Long COVID risk, yet no evidence has been established regarding sex differences in the relationship between BMI and the risk of Long COVID. Investigating the nature of this relationship was the main objective of this study.
METHODS: A population-based prospective study involving a sample of respondents aged 50 years and older (n = 4004) from 27 European countries that participated in the 2020 and 2021 Survey of Health, Ageing and Retirement in Europe's (SHARE) Corona Surveys and in Waves 7 and 8 of the main SHARE survey. Logistic regression models were estimated to produce unadjusted and adjusted estimates of the sex differences in the relationship between BMI and Long COVID.
RESULTS: Linear relationship for females, with probability of Long COVID increasing with BMI (68% at BMI = 18, 93% at BMI = 45). Non-linear relationship for males, with probability of Long COVID of 27% at BMI = 18, 68% at BMI = 33, and 40% at BMI = 45. Relationships remained significant after adjusting for known Long COVID risk factors (age and COVID-19 hospitalization), presence of chronic diseases, and respondents' place of residence.
CONCLUSION: Sex differences appear to play an important role in the relationship between BMI and risk of Long COVID. Overall, females were more likely to have Long COVID, regardless of their BMI. Males at the higher end of the BMI spectrum had a lower risk of Long COVID as opposed to their female counterparts. Sex-specific research is recommended for better understanding of Long COVID risk factors.
The effects of Crizanlizumab will be assessed in 20 nontransfused SCD subjects. After comprehensive baseline assessment one month prior the time of study initiation, patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses). Safety laboratories will be drawn at each infusion visit. There will be a follow up phone call the day after receiving the medication. Comprehensive blood and vascular testing will be repeated at Week 11 and Week 23 of treatment.
PURPOSE:To remarkably improve the qualities such as gloss, applicability and usability of lipstick, etc., on an industrial scale at a low cost by adding a rosin to the component of lipstick, etc. CONSTITUTION:Rosin of a resin produced by removing essential oils from the secrete of bark of Pinus palustris MILL. belonging to family Pinaceae is added to the component of lipstick or lip cream to improve the quality of the lipstick or lip cream. The amount of the rosin in the composition of lipstick, etc., is preferably 0.5-20wt.%. Rosin is added to the base raw material of the lipstick or lip cream and the mixture is completely melted by heating. The addition of rosin decreases the stickiness, improves the adhesivity to the skin, suppresses the variation of hardness with temperature and gives a lipstick, etc., having high luster. The lipstick, etc., is free from blooming with time.
PROBLEM TO BE SOLVED: To provide a solid pharmaceutical product for photodynamic treatment of such as cervical cancer.SOLUTION: The solid pharmaceutical product contains a photosensitizer which is 5-aminolevulinic acid ester (5-ALA ester) represented by formula (I) or a pharmaceutically acceptable salt thereof, and at least one of pharmaceutically acceptable carrier or excipient. The pharmaceutically acceptable carrier or excipient is hard fat or a mixture of the hard fat and an additive. The solid pharmaceutical product is in the form of a suppository. The solid pharmaceutical product is preferably adapted for insertion into the uterus, vagina or cervix. The melting point thereof is preferably 30 to 37°C. The melting point of the mixture of the hard fat and the additive is preferably 31 to 33°C. Formula (I) is RN-CHCOCH-CHCO-OR, where Rrepresents a substituted or unsubstituted, straight-chained, branched or cyclic alkyl group, and each Rindependently represents a hydrogen atom.
Before treatment, the patients in the study group underwent NGS detection of ctDNA and formulated endocrine treatment plan according to the test results. After 2 months of endocrine therapy, all patients underwent NGS detection of ctDNA, and the efficacy was evaluated according to RECIST v1.1 standard.
This study is a multicenter study, designed to determine the efficacy of the Hair2Go hair removal device and to compare the extent of hair removal with and without maintenance treatments. Preferably, two anatomical regions to be treated will be selected including the axilla and either the legs (calves) or forearms. The size of the area treated will be approximately 5x5 cm2. Additional areas including the face can be treated according to the subject's request with the PI's discretion but are not mandatory. Subjects will be provided with the device and will be instructed as to the method of usage. The subjects will be expected to self-administer the treatment at the clinic in a "simulated home environment". The duration of the treatment session is approximately 30-60 minutes. Each of the selected anatomical regions (both left and right sides) will be treated with either low, medium, or high Elōs energy level according to the PI's discretion. However all anatomical regions except for the axilla will be treated with either low or medium elōs energy levels only. Only the axilla will be treated up to an energy of 4J//cm2 A defined area of 5x5 cm2cm2 in the leg will not be treated and will serve as a reference for the temporal changes in hair growth that might be subject to factors, including fluctuations in hormone levels. Both sides (left and right) of the same anatomical region will receive the basic treatments. One side will receive 3 additional maintenance treatments in 4 week intervals ("Maintenance" vs "No maintenance" side) until the end of the experiment. More specifically, the study includes up to 11 visits at the clinic: initial consultation, 7 basic treatments in 1 week intervals followed in one side by 3 maintenance treatments, each 4 weeks apart. Follow ups will be conducted at 4 and 12 weeks after the last basic treatment.
Patients will be prescribed Flomax 0.4Mg Capsule and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
OBJECTIVE: Tranexamic acid (TXA) is an FDA-approved antifibrinolytic that is seeing increased popularity in spine surgery owing to its ability to reduce intraoperative blood loss (IOBL) and allogeneic transfusion requirements. The present study aimed to summarize the current literature on these formulations in the context of short-segment instrumented lumbar fusion including ≥ 1-level posterior lumbar interbody fusion (PLIF).
METHODS: The PubMed, Cochrane, and Web of Science databases were queried for all full-text English studies evaluating the use of topical TXA (tTXA), systemic TXA (sTXA), or combined tTXA+sTXA in patients undergoing PLIF. The primary endpoints of interest were operative time, IOBL, and total blood loss (TBL); secondary endpoints included venous thromboembolic complication occurrence, and allogeneic and autologous transfusion requirements. Outcomes were compared using random effects. Comparisons were made between the following treatment groups: sTXA, tTXA, and sTXA+tTXA. Given that sTXA is arguably the standard of care in the literature (i.e., the most common route of administration that to this point has been studied the most), the authors compared sTXA versus tTXA and sTXA versus sTXA+tTXA. Study heterogeneity was assessed with the I2 test, and grouped analysis using the Hedge's g test was performed for measurement of effect size.
RESULTS: Forty-five articles were identified, of which 17 met the criteria for inclusion with an aggregate of 1008 patients. TXA regimens included sTXA only, tTXA only, and various combinations of sTXA and tTXA. There were no significant differences in operative time, TBL, or postoperative drainage between the sTXA and tTXA groups or between the sTXA and sTXA+tTXA groups.
CONCLUSIONS: The present meta-analysis suggested clinical equipoise between isolated sTXA, isolated tTXA, and combinatorial tTXA+sTXA formulations as hemostatic adjuvants/neoadjuvants in short-segment fusion including ≥ 1-level PLIF. Given the theoretically lower venous thromboembolism risk associated with tTXA, additional investigations using large cohorts comparing these two formulations within the posterior fusion population are merited. Although TXA has been shown to be effective, there are insufficient data to support topical or systemic administration as superior within the open PLIF population.
In this 24 week randomized controlled trial, hospitalized insulin-requiring patients with type 2 diabetes and poor glycemic control (HbA1c \>8.5%) will receive standard of care insulin therapy including basal insulin glargine U300 (TOUJEO®) plus additional background therapy (non-insulin and prandial insulin therapies) with either a diabetes focused discharge order set (DOS) and follow-up communication to facilitate insulin titration and outpatient follow-up or enhanced standard care (ESC). 222 patients (type 2 diabetes) will be recruited. Hospitalized patients with type 2 diabetes (HbA1c \>8.5%) who are receiving basal insulin at least 10 unit per day and are able to provide informed consent and complete study procedures will be approached. All patients will be discharged on glargine U300 with initial doses determined by the discharging team. Patients in the DOS group will receive instructions for self-titration of basal insulin as part of the discharge order. The DOS contains a comprehensive checklist for basic diet, hospital follow-up, glucose targets and instructions for monitoring, insulin pens and pen needles, glucose testing supplies, and ancillary orders. Patients will have follow-up phone calls at week 2, 6, and in-person visits at week 12 and 24. Phone calls will assess adherence with instructions for self-titration in the DOS group but are information gathering only in the ESC group, and questions related to care will be referred to the usual provider. Glucose lowering medication management following discharge will otherwise be conducted by the patient's usual or designated standard of care provider. The study and all study-related documents will be approved by the OSU IRB. All data analyses will be completed as intention to treat analyses. Longitudinal outcomes (e.g., HbA1c) will be analyzed using mixed models utilizing all available measurements from individuals randomized.
PROBLEM TO BE SOLVED: To provide a cosmetic composition using Panax ginseng C.A. fruits which is applicable to the skin cosmetic and is harmless to human bodies, and has an extremely high safety.SOLUTION: The invention provides a cosmetic composition containing, as an active ingredient, an extract produced by fermenting Panax ginseng C.A. fruits extract with Pleurotus ferulae mycelium; and the fermented solution. It is confirmed that the fermented solution of Panax ginseng C.A. fruits with Pleurotus ferulae significantly increases an antioxidation and anti-inflammation, collagen synthesis promotion, skin wrinkle improvement, whitening, moisturization, skin barrier function improvement, and atopy improvement effect, compared with the simple extract of Panax ginseng C.A. fruits.
STRICT ASEPTIC TECHNIQUE IS MANDATORY. The vial should be shaken before use to ensure a uniform suspension. Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration). An agglomerated product results from exposure to freezing temperatures and should not be used. After withdrawal, Kenalog-40 Injection should be injected without delay to prevent settling in the syringe. Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing infection.
FIELD: veterinary science, vaccines. SUBSTANCE: invention relates to preparing live cultural vaccines against smallpox in sheep. Method involves preparing sowing sets of transplantable sheep kidney cells (sublines PO-VNIIVViM) in roller flasks. Formed monolayer is infected with sowing virus at the optimal dose. Infected culture is incubated under roller conditions for 5-6 days and the supporting medium is changed in every 2-3 days of culturing. Cultures at the degree of the damage by 75-80% are frozen at -40 C and thawed at the room temperature. Obtained virus-containing raw is mixed with protective medium of the definite composition at their volume ratio = 1:1 followed by lyophilic drying up to the content of moisture 4%, not above. Invention provides preparing the standard, harmless, highly immune and stable at storage vaccine against smallpox in sheep. EFFECT: improved quality and properties of vaccine, highly productive technology of preparing. 1 tbl, 4 ex
Septic cardiomyopathy is a life-threatening heart dysfunction caused by severe infection. Considering the complexity of pathogenesis and high mortality, the identification of efficient biomarkers are needed to guide clinical practice. Based on multimicroarray analysis, this study aimed to explore the pathogenesis of septic cardiomyopathy and the related immune landscape. The results showed that septic cardiomyopathy resulted in organ dysfunction due to extreme pro- and anti-inflammatory effects. In this process, KLRG1, PRF1, BCL6, GAB2, MMP9, IL1R1, JAK3, IL6ST, and SERPINE1 were identified as the hub genes regulating the immune landscape of septic cardiomyopathy. Nine transcription factors regulated the expression of these genes: SRF, STAT1, SP1, RELA, PPARG, NFKB1, PPARA, SMAD3, and STAT3. The hub genes activated the Th17 cell differentiation pathway, JAK-STAT signaling pathway, and cytokine‒cytokine receptor interaction pathway. These pathways were mainly involved in regulating the inflammatory response, adaptive immune response, leukocyte-mediated immunity, cytokine-mediated immunity, immune effector processes, myeloid cell differentiation, and T-helper cell differentiation. These nine hub genes could be considered biomarkers for the early prediction of septic cardiomyopathy.
A reusable surgical model of the eye has mating anterior and posterior segments. The posterior segment has structures corresponding to those of the eye, including a hollow globe and an image of the fundus positioned upon an interior, posterior portion of the globe. A mating connector is peripherally formed about an open end of the globe. The anterior segment includes structures corresponding to those of the eye, including a pars plana, an opening in a region corresponding to an iris, and a lens positionable within the opening. The anterior segment has a peripheral connector which mates with that of the posterior segment. The lens is removably connected to the anterior segment, and has a focal length corresponding to a natural eye. A coating is applied to the fundus to enable simulation of a membrane peeling procedure, and the globe is fillable with a vitreous substitute.
The intervention group will participate in GMT, a standardized cognitive rehabilitation program which will be given as per the manual and which consists of 9 sessions each 2-hours in duration. They will also participate in the Healthy Lifestyle Program (HLP), which includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
PROBLEM TO BE SOLVED: To provide a dentifrice useful for medical treatment, prevention of alveolar pyorrhea by improving the blood circulation of gums. SOLUTION: This dentifrice uses a conventional dentifrice mixed with a spice (e.g.; Guinea pepper). This dentifrice prevents, cures the alveolar pyorrhea of gums by using the spice effects of Guinea pepper, etc., such as improving the blood circulation effect, bactericidal action, deodorizing action. Pulmonary tuberculosis of a bedridden old man caused by penetration of saliva into bronchial tube can be prevented by the bactericidal action accompanied by daubing the dentifrice containing spice, cream with a spice, jelly on a gum. Using these blood circulation improving effect of the spice, this dentifrice is capable of curing interruption in blood circulation part of the body, chilblain in winter.
Data that is routinely collected as part of standard of care intraoperative monitoring including blood pressure, amount of anesthetic administered and a form of processes electroencephalogram called the bispectral index, which is a measure of depth of anesthesia all enter in an electronic record keeper. This project monitors for a combination of a blood pressure below mean of 75mmHg and a BIS of 45. When this is detected, half of the anesthesiologists caring for patients receive a text message on the computer screen and their pagers indicating that a double low situation exists and that they should consider intervening. The other half of practitioners are not provided with the additional messages, although all of the same information is available in the operating room (OR). Most patients undergoing general non-cardiac anesthesia at Mount Sinai are eligible. Documentation of consent was waived. All patients are informed of the ongoing project upon admission and are given a variety of methods of opting out of the project.

The analysis seeks to determine if the messages were effective at influencing clinician behavior and whether that change would make a difference in either length of stay or 90 day mortality.
Adult patients with clinically documented complicated skin and skin structure infections (cSSSI) were enrolled in two randomized, multinational, multicenter, double-blinded trials (Trial 1 and Trial 2) comparing VIBATIV (10 mg/kg IV every 24 hours) with vancomycin (1 g IV every 12 hours) for 7 to 14 days. Vancomycin dosages could be adjusted per site-specific practice. Patients could receive concomitant aztreonam or metronidazole for suspected Gram-negative and anaerobic infection, respectively. These trials were identical in design, enrolling approximately 69% of their patients from the United States. 

The trials enrolled adult patients with cSSSI with suspected or confirmed MRSA as the primary cause of infection. The all-treated efficacy (ATe) population included all patients who received any amount of study medication according to their randomized treatment group and were evaluated for efficacy. The clinically evaluable population (CE) included patients in the ATe population with sufficient adherence to the protocol. 

The ATe population consisted of 1,794 patients. Of these, 1,410 (79%) patients were clinically evaluable (CE). Patient baseline infection types were well-balanced between treatment groups and are presented in Table 9. 

The primary efficacy endpoints in both trials were the clinical cure rates at a follow-up (Test-of-Cure) visit in the ATe and CE populations. Clinical cure rates in Trials 1 and 2 are displayed for the ATe and CE population in Table 10. 

The cure rates by pathogen for the microbiologically evaluable (ME) population are presented in Table 11. 

Of the 1784 patients in the ATe population in the two cSSSI trials, 32 patients had baseline S. aureus bacteremia: 21 patients (2.4%, including 13 with MRSA) were treated with VIBATIV and 11 patients (1.2%, including 4 with MRSA) were treated with vancomycin. In these bacteremic patients, the clinical cure rate at Test-of-Cure was 57.1% (12/21) for the VIBATIV-treated patients and 54.6% (6/11) for the vancomycin-treated patients. Given the limited sample size in this subgroup, the interpretation of these results is limited. 

In the two cSSSI trials, clinical cure rates were similar across gender and race. Clinical cure rates in the VIBATIV clinically evaluable (CE) population were lower in patients ≥65 years of age compared with those <65 years of age. A decrease of this magnitude was not observed in the vancomycin CE population. Clinical cure rates in the VIBATIV CE population <65 years of age were 503/581 (87%) and in those ≥65 years were 88/122 (72%). In the vancomycin CE population clinical cure rates in patients <65 years of age were 492/570 (86%) and in those ≥65 years was 111/137 (82%). Clinical cure rates in the VIBATIV-treated patients were lower in patients with baseline CrCl ≤50 mL/min compared with those with CrCl >50 mL/min. A decrease of this magnitude was not observed in the vancomycintreated patients [see Warnings and Precautions (5.2)].
<P>PROBLEM TO BE SOLVED: To provide an automatic glycoprotein refining apparatus for automatically, aseptically, securely and efficiently refining a glycoprotein such as fibronectin etc. from blood plasma and a solution cartridge, a column cartridge and a flow path cartridge simply and securely used in the refining apparatus.  <P>SOLUTION: A blood plasma container 45 for accommodating the blood plasma, a first buffer solution container 44 filled with a first buffer solution, an eluate container 43 filled with an eluate and a second buffer solution container 42 filled with a second buffer solution are integrated into the solution cartridge 4. The solution cartridge 4 is mounted to a solution cartridge mount 21 of a cartridge mount 2 provided in a body 1. The column cartridge 5 is mounted to a column cartridge mount 22. The flow path cartridge 6 is mounted to a flow path cartridge mount 23.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
PURPOSE: We herein present Descemet membrane endothelial keratoplasty (DMEK) as an effective surgical means of treatment for the management of interface fluid syndrome (IFS) in a series of cases with distant history of laser in situ keratomileusis (LASIK).
METHODS: Three cases from a single institution were included. All patients had documented IFS in the setting of history of LASIK. All 3 patients underwent DMEK for the treatment of IFS. Visual acuity, clinical findings, pachymetry, endothelial cell count, and anterior segment optical coherence tomography were recorded.
RESULTS: We describe 3 cases of late-onset IFS that developed in eyes many years after LASIK (ranging from 15 to 31 years). All 3 patients had clinically significant corneal edema and evidence of poor endothelial function at the time of IFS diagnosis. DMEK was subsequently performed in each case. All 3 eyes showed resolution of corneal edema and improvement in best-corrected visual acuity after DMEK.
CONCLUSIONS: DMEK can provide successful visual and anatomical recovery in patients who have had previous LASIK and experience late-onset IFS due to endothelial cell dysfunction.
Surgeons who started performing LDP during phase 2 of the IDEAL framework; the Development and Exploration phase. They did not receive any specific form of training and were therefore considered self-taught.